You have 8 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

taxane platinum resistant

Showing 1 - 25 of 7,438
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Platinum-resistant Ovarian Cancer, Platinum-refractory Ovarian Cancer, Fallopian Tube Cancer Trial in Orlando, Albuquerque

Recruiting
  • Platinum-resistant Ovarian Cancer
  • +6 more
  • olvimulogene nanivacirepvec
  • +3 more
  • Orlando, Florida
    AdventHealth Cancer Institute
Sep 1, 2022

Small Cell Carcinoma, NSCLC, Neuroendocrine Tumors Trial in United States (RRx-001, Cisplatin, Etoposide)

Active, not recruiting
  • Small Cell Carcinoma
  • +3 more
  • Palo Alto, California
  • +9 more
May 12, 2022

Platinum-resistant Ovarian Cancer

Not yet recruiting
  • Ovarian Cancer
  • pegylated liposomal doxorubicin
  • (no location specified)
Aug 2, 2023

Ovarian Cancer, Platinum-resistant Ovarian Cancer Trial in Minsk (Gemcitabine, ELENAGEN)

Active, not recruiting
  • Ovarian Cancer
  • Platinum-resistant Ovarian Cancer
  • Minsk, Belarus
    Minsk City Clinical Oncology Center
Jul 27, 2023

Ovarian Cancer Recurrent Trial (Fluzopril Combined With Apatinib)

Not yet recruiting
  • Ovarian Cancer Recurrent
  • Fluzopril Combined With Apatinib
  • (no location specified)
Oct 22, 2023

Ovarian High Grade Serous Adenocarcinoma, Platinum-Resistant Ovarian Carcinoma Trial in Atlanta (Atovaquone, Biopsy, Computed

Not yet recruiting
  • Ovarian High Grade Serous Adenocarcinoma
  • Platinum-Resistant Ovarian Carcinoma
  • Atlanta, Georgia
    Emory University Hospital/Winship Cancer Institute
Aug 11, 2023

Metastatic Castration-Resistant Prostate Cancer (mCRPC) Trial ([177Lu]Lu-PSMA-617, ARDT, [68Ga]Ga-PSMA-11)

Not yet recruiting
  • Metastatic Castration-Resistant Prostate Cancer (mCRPC)
  • (no location specified)
Jan 23, 2023

Chemotherapeutic Toxicity Trial (Home Based Walking Program)

Not yet recruiting
  • Chemotherapeutic Toxicity
  • Home Based Walking Program
  • (no location specified)
Aug 28, 2023

Aggressive Variant Prostate Carcinoma, Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma Trial in Houston

Recruiting
  • Aggressive Variant Prostate Carcinoma
  • +5 more
  • Houston, Texas
    M D Anderson Cancer Center
Feb 10, 2022

Advanced Solid Tumor, Platinum-resistant Ovarian Cancer Trial (SON-1010)

Not yet recruiting
  • Advanced Solid Tumor
  • Platinum-resistant Ovarian Cancer
  • SON-1010
  • (no location specified)
Mar 10, 2023

Platinum-resistant Ovarian Cancer Trial in Shanghai (Oral Topotecan Combined With Anlotinib)

Not yet recruiting
  • Platinum-resistant Ovarian Cancer
  • Oral Topotecan Combined With Anlotinib
  • Shanghai, China
    Xinhua Hospital Affiliated to Shanghai Jiaotong University Schoo
Feb 12, 2023

Malignant Ovarian Epithelial Tumor, Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma Trial in

Recruiting
  • Malignant Ovarian Epithelial Tumor
  • +9 more
  • Akt/ERK Inhibitor ONC201
  • +2 more
  • Detroit, Michigan
    Barbara Ann Karmanos Cancer Institute
May 10, 2022

Ovarian Carcinoma Trial in New Haven (Sacituzumab govitecan)

Not yet recruiting
  • Ovarian Carcinoma
  • Sacituzumab govitecan
  • New Haven, Connecticut
    Smilow Cancer Hospital at Yale New Haven
Aug 31, 2023

Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal

Not yet recruiting
  • Platinum-Resistant Fallopian Tube Carcinoma
  • +5 more
  • Biopsy
  • +4 more
  • Duarte, California
    City of Hope Medical Center
Jan 3, 2023

Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma, PARP Inhibitor Trial in Pittsburgh

Not yet recruiting
  • Platinum-Resistant Fallopian Tube Carcinoma
  • +3 more
  • Pittsburgh, Pennsylvania
    UPMC Hillman Cancer Center
Sep 8, 2022

PARP Inhibitor Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients Not Candidate for Platinum Retreatment

Recruiting
  • PARP Inhibitor Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients Not Candidate for Platinum Retreatment
  • Seoul, Korea, Republic of
    Yonsei University Health System, Severance Hospital
Dec 4, 2022

Ovarian Tumors, Ovarian Diseases Trial (Adebrelimab, Fuzuloparib)

Not yet recruiting
  • Ovarian Neoplasms
  • Ovarian Diseases
  • (no location specified)
Feb 23, 2023

Cytoreductive Surgery Trial in Hangzhou (cytoreductive surgery)

Not yet recruiting
  • Cytoreductive Surgery
  • cytoreductive surgery
  • Hangzhou, China
  • +1 more
Nov 30, 2022

Ovarian Cancer Recurrent Trial in Beijing (IN10018, Placebo of IN10018, Pegylated Liposomal Doxorubicin)

Recruiting
  • Ovarian Cancer Recurrent
  • Beijing, China
    Cancer Hospital Chinese Academy of Medical Science and Peking Un
Aug 23, 2023

Ovarian Cancer Trial in Houston (Nivolumab, Etigilimab)

Not yet recruiting
  • Ovarian Cancer
  • Houston, Texas
    M D Anderson Cancer Center
Jan 27, 2023

Platinum-Refractory Fallopian Tube Carcinoma, Platinum-Refractory Ovarian Carcinoma, Platinum-Refractory Primary Peritoneal

Recruiting
  • Platinum-Refractory Fallopian Tube Carcinoma
  • +11 more
  • Copanlisib Hydrochloride
  • +4 more
  • Aurora, Colorado
  • +2 more
Dec 8, 2022

Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal

Completed
Has Results
  • Platinum-Resistant Fallopian Tube Carcinoma
  • +8 more
  • Bevacizumab
  • Irinotecan Sucrosofate
  • Chicago, Illinois
    Northwestern University
Dec 21, 2022

Platinum-resistant Epithelial Ovarian Cancer Trial in Ocala, Mineola (Maveropepimut-S, Cyclophosphamide 50mg)

Recruiting
  • Platinum-resistant Epithelial Ovarian Cancer
  • Maveropepimut-S
  • Cyclophosphamide 50mg
  • Ocala, Florida
  • +1 more
Jul 20, 2022

Platinum-resistant Ovarian Cancer, Fallopian Tube Cancer, Epithelial Ovarian Cancer Trial (Pegylated Liposomal Doxorubicin +

Not yet recruiting
  • Platinum-resistant Ovarian Cancer
  • +6 more
  • Pegylated Liposomal Doxorubicin + SL-172154
  • Mirvetuximab + SL-172154
  • (no location specified)
Jul 29, 2022

Urothelial Carcinoma Trial in Iowa City (Avelumab, Docetaxel)

Active, not recruiting
  • Urothelial Carcinoma
  • Iowa City, Iowa
    University of Iowa Hospitals and Clinics
Oct 18, 2022